117 related articles for article (PubMed ID: 11249145)
1. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy.
Mclay LM; Halley F; Souness JE; McKenna J; Benning V; Birrell M; Burton B; Belvisi M; Collis A; Constan A; Foster M; Hele D; Jayyosi Z; Kelley M; Maslen C; Miller G; Ouldelhkim MC; Page K; Phipps S; Pollock K; Porter B; Ratcliffe AJ; Redford EJ; Webber S; Slater B; Thybaud V; Wilsher N
Bioorg Med Chem; 2001 Feb; 9(2):537-54. PubMed ID: 11249145
[TBL] [Abstract][Full Text] [Related]
2. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
4. An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors.
McKenna JM; Halley F; Souness JE; McLay IM; Pickett SD; Collis AJ; Page K; Ahmed I
J Med Chem; 2002 May; 45(11):2173-84. PubMed ID: 12014955
[TBL] [Abstract][Full Text] [Related]
5. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.
Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Rucklin G
Bioorg Med Chem Lett; 2004 Jul; 14(13):3595-9. PubMed ID: 15177482
[TBL] [Abstract][Full Text] [Related]
6. RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.
Collis AJ; Foster ML; Halley F; Maslen C; McLay IM; Page KM; Redford EJ; Souness JE; Wilsher NE
Bioorg Med Chem Lett; 2001 Mar; 11(5):693-6. PubMed ID: 11266171
[TBL] [Abstract][Full Text] [Related]
7. A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.
Brown DS; Belfield AJ; Brown GR; Campbell D; Foubister A; Masters DJ; Pike KG; Snelson WL; Wells SL
Bioorg Med Chem Lett; 2004 Nov; 14(21):5383-7. PubMed ID: 15454231
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase.
Stelmach JE; Liu L; Patel SB; Pivnichny JV; Scapin G; Singh S; Hop CE; Wang Z; Strauss JR; Cameron PM; Nichols EA; O'Keefe SJ; O'Neill EA; Schmatz DM; Schwartz CD; Thompson CM; Zaller DM; Doherty JB
Bioorg Med Chem Lett; 2003 Jan; 13(2):277-80. PubMed ID: 12482439
[TBL] [Abstract][Full Text] [Related]
9. p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappa B-independent mechanism.
Meja KK; Seldon PM; Nasuhara Y; Ito K; Barnes PJ; Lindsay MA; Giembycz MA
Br J Pharmacol; 2000 Nov; 131(6):1143-53. PubMed ID: 11082122
[TBL] [Abstract][Full Text] [Related]
10. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation.
Mourey RJ; Burnette BL; Brustkern SJ; Daniels JS; Hirsch JL; Hood WF; Meyers MJ; Mnich SJ; Pierce BS; Saabye MJ; Schindler JF; South SA; Webb EG; Zhang J; Anderson DR
J Pharmacol Exp Ther; 2010 Jun; 333(3):797-807. PubMed ID: 20237073
[TBL] [Abstract][Full Text] [Related]
11. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
Wadsworth SA; Cavender DE; Beers SA; Lalan P; Schafer PH; Malloy EA; Wu W; Fahmy B; Olini GC; Davis JE; Pellegrino-Gensey JL; Wachter MP; Siekierka JJ
J Pharmacol Exp Ther; 1999 Nov; 291(2):680-7. PubMed ID: 10525088
[TBL] [Abstract][Full Text] [Related]
12. Imidazopyrimidines, potent inhibitors of p38 MAP kinase.
Rupert KC; Henry JR; Dodd JH; Wadsworth SA; Cavender DE; Olini GC; Fahmy B; Siekierka JJ
Bioorg Med Chem Lett; 2003 Feb; 13(3):347-50. PubMed ID: 12565927
[TBL] [Abstract][Full Text] [Related]
13. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst J; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Eur J Pharmacol; 2010 Apr; 632(1-3):93-102. PubMed ID: 20132813
[TBL] [Abstract][Full Text] [Related]
14. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
[TBL] [Abstract][Full Text] [Related]
15. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.
Badger AM; Griswold DE; Kapadia R; Blake S; Swift BA; Hoffman SJ; Stroup GB; Webb E; Rieman DJ; Gowen M; Boehm JC; Adams JL; Lee JC
Arthritis Rheum; 2000 Jan; 43(1):175-83. PubMed ID: 10643714
[TBL] [Abstract][Full Text] [Related]
16. p38 MAP kinase inhibitors. Part 5: discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold.
Natarajan SR; Liu L; Levorse M; Thompson JE; O'Neill EA; O'Keefe SJ; Vora KA; Cvetovich R; Chung JY; Carballo-Jane E; Visco DM
Bioorg Med Chem Lett; 2006 Oct; 16(20):5468-71. PubMed ID: 16945534
[TBL] [Abstract][Full Text] [Related]
17. Discovery of pyridazinopyridinones as potent and selective p38 mitogen-activated protein kinase inhibitors.
Wu B; Wang HL; Pettus L; Wurz RP; Doherty EM; Henkle B; McBride HJ; Saris CJ; Wong LM; Plant MH; Sherman L; Lee MR; Hsieh F; Tasker AS
J Med Chem; 2010 Sep; 53(17):6398-411. PubMed ID: 20712346
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel inhibitor of LPS-induced TNF-alpha production with antiproliferative activity in monocyte/macrophages.
Nagahira A; Nagahira K; Murafuji H; Abe K; Magota K; Matsui M; Oikawa S
Biochem Biophys Res Commun; 2001 Mar; 281(4):1030-6. PubMed ID: 11237767
[TBL] [Abstract][Full Text] [Related]
19. Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness.
Faas MM; Moes H; Fijen JW; Muller Kobold AC; Tulleken JE; Zijlstra JG
Clin Exp Immunol; 2002 Feb; 127(2):337-43. PubMed ID: 11876759
[TBL] [Abstract][Full Text] [Related]
20. [Synergetic effect of mitogen-activated protein kinase pathway on expression of tumor necrosis factor alpha gene in RAW 264.7 cells induced by lipopolysaccharide].
Jiang Y; Liu A; Qin Q; Yin Z
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(20):1410-4. PubMed ID: 12509925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
